Kexing Biopharm Co.,Ltd. (688136.SH) has announced that it recently received a Notice of Acceptance from the National Medical Products Administration regarding the marketing authorization application for its investigational drug, pegylated human granulocyte colony-stimulating factor injection (referred to as "GB-K02").

GB-K02 is intended for use in patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is prone to causing clinically significant febrile neutropenia, in order to reduce the incidence of infections manifested as febrile neutropenia.